Biogen Inc (NASDAQ: BIIB) kicked off on Tuesday, down -4.74% from the previous trading day, before settling in for the closing price of $150.18. Over the past 52 weeks, BIIB has traded in a range of $145.07-$252.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -7.03% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 11.55%. With a float of $144.68 million, this company’s outstanding shares have now reached $145.70 million.
In an organization with 7570 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 71.81%, operating margin of 21.11%, and the pretax margin is 20.27%.
Biogen Inc (BIIB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Biogen Inc is 0.71%, while institutional ownership is 89.49%. The most recent insider transaction that took place on Dec 09 ’24, was worth 17,293. In this transaction Head of Development of this company sold 110 shares at a rate of $157.21, taking the stock ownership to the 5,426 shares. Before that another transaction happened on Dec 09 ’24, when Company’s Officer proposed sale 110 for $157.21, making the entire transaction worth $17,293.
Biogen Inc (BIIB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.00% during the next five years compared to -18.05% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Take a look at Biogen Inc’s (BIIB) current performance indicators. Last quarter, stock had a quick ratio of 0.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.26. Likewise, its price to free cash flow for the trailing twelve months is 10.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.07, a number that is poised to hit 3.41 in the next quarter and is forecasted to reach 16.66 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.25 million. That was better than the volume of 1.23 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.78%. Additionally, its Average True Range was 3.87.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 0.98%, which indicates a significant decrease from 4.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.95% in the past 14 days, which was higher than the 21.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $157.95, while its 200-day Moving Average is $196.46. However, in the short run, Biogen Inc’s stock first resistance to watch stands at $148.05. Second resistance stands at $153.03. The third major resistance level sits at $155.85. If the price goes on to break the first support level at $140.25, it is likely to go to the next support level at $137.43. The third support level lies at $132.45 if the price breaches the second support level.
Biogen Inc (NASDAQ: BIIB) Key Stats
The company with the Market Capitalisation of 20.85 billion has total of 145,719K Shares Outstanding. Its annual sales at the moment are 9,836 M in contrast with the sum of 1,161 M annual income. Company’s last quarter sales were recorded 2,466 M and last quarter income was 388,500 K.
